Designs for Clinical Trials
|
|
- Hilary Nash
- 5 years ago
- Views:
Transcription
1 Designs for Clinical Trials
2 Design issues Research question Statistical optimality not enough! Use simulation models! Confounding Objective Control Statistics Design, Variables Ethics Variability Cost Feasibility
3
4 Parallel Group Designs R Test Control Control Easy to implement ccepted Easy to analyse Good for acute conditions Yij i i,,n j ij j,,k ~ N, ij
5 Where does the varation go? Placebo Drug X 8 week blood pressure Y Xβ ε nything we can explain Unexplained
6 etween and within subject variation DP mmhg Placebo Drug X Female Male aseline 8 weeks
7
8
9
10
11
12 Variance formulas for equations on prev slide Only end of study: Var[ ] Y end Change from baseline Var[ Y end Y baseline Corr[ Y ] Var[ Y end, Y end baseline ] Var[ Y ] baseline aseline as covariate: Some other time ] Cov[ Y Corr[ Y end, Y end, Y baseline baseline ] ]
13
14
15 Model for a cross over study Obs=Period+sequence+subject+treament+carryover+error Yijk i effect of sequence i, i( k) effect of subject k,, ni within sequence i iid N, j effect of period j, t effect of treatment t, random error iid N, ijk i i( k) j t j r ijk s
16 by Crossover design E Y ijk Effect of treatment and carry over can not be separated!
17 Model: Sum to zero: Matrix formulation Yijk Matrix formulation,, i i( k) X, T T X j t ijk (Restrictions madeso these parameters become uniquely defined and not only up to some additive constants)
18 Matrix formulation Parameter estimate: X T X X T Y ˆ ˆ T Y Y T X ˆ Y Cov ˆ X T X ˆ X T X Estimates independent and Var ˆ.5 ˆ
19 lternatives to * Compare to Same model but with 3 periods and a carry over effect Yijk i i( k) i j i( k) effect of subject k,, ni within sequence i iid N, effect effect of of sequence period i, j,,3 t effect of treatment t, random error iid N, ijk j t j r ijk s
20 Parameters of the, design Yijk i i k j t ( ) ijk E Y ijk ijk
21 Matrix again X X T X Effect of treatment and carry over can be estimated independently!
22 Other sequence 3 period designs 3 4 Var ˆ Var ˆ Corr ˆ, ˆ N/.5.. N/ N/
23 Comparing the, and the, designs Var ˆ.5 ˆ ˆ Var.9 ˆ Can t include carry over Carry over estimable treatments per subject 3 treatments per subject Shorter duration Longer duration
24 More than treatments Tool of the trade: Define the model X T X C C C C C C D C D C C D C D Investigate C C C C C Watch out for drop outs!
25 Titration Designs Increasing dose panels (Phase I): SD (Single scending Dose) MD (Multiple scending Dose) Primary Objective: Establish Safety and Tolerability Estimate Pharmaco Kinetic (PK) profile Increasing dose panelse (Phase II): Dose - response
26 VERY careful with first group! Titration Designs (SD, MD) Dose: Z mg X on drug Y on Placebo Dose: Z mg X on drug Y on Placebo Dose: Z k mg X on drug Y on Placebo Stop if any signs of safety issues
27 Titration Designs Which dose levels? Start dose based on exposure in animal models. Stop dose based on toxdata from animal models. Doses often equidistant on log scale. Which subject? Healty volunteers Young Male How many subjects? Rarely any formal power calculation. Often on placebo and 6-8 on drug.
28 Titration Designs Not mandatory to have new subject for each group. X mg X mg X 3 mg X 4 mg X 5 mg X Y mg Gr. Gr. Gr. Gr. Gr. 3 Gr Slighty larger groups to have sufficiently many exposed. Dose in fourth group depends on results so far. Possible to estimate within subject variation.
29 Factorial design clinical trials Factorial randomised trials allows to evaluate more than one intervention in a single experiment, whether () testing the treatment effects independently or () when the aim is to investigate the treatment interactions. In the simplest case, a design is a study when two treatment factors are involved each with two levels. nalysis of factorial trials requires more attention than simple parallel studies. Specifically, choice of statistical methods and how to handle treatment interactions.
30 Factorial design clinical trials For example, in a cardiovascular disease prevention trial, patients are being randomized to receive aspirin vs. matching placebo and then betacarotene vs. matching placebo. eta-carotene Yes spirin No Yes Group spirin + eta-carotene Group spirin placebo + eta-carotene No Group 3 spirin + eta-carotene placebo Group 4 spirin placebo + eta-carotene placebo
31 Factorial design Evaluation of a fixed combination of drug and drug placebo placebo active placebo P placebo active active active The U.S. FD s policy ( CFR 3.5) regarding the use of a fixed-dose combination The agency requires: Each component must make a contribution to the claimed effect of the combination. Implication: t specific component doses, the combination must be superior to its components at the same respective doses
32 daptive Designs Dragalin V. daptive Designs: Terminology and Classification. Drug Information Journal. 6; 4(4):
33
34
35 Definition daptive Design uses accumulating data to decide on how to modify aspects of the study without undermining the validity and integrity of the trial Validity means providing correct statistical inference (such as adjusted p- values, unbiased estimates and adjusted confidence intervals, etc) assuring consistency between different stages of the study minimizing operational bias Integrity means providing convincing results to a broader scientific community preplanning, as much as possible, based on intended adaptations maintaining confidentiality of data
36 daptive Plan not daptive Plane n adaptive design should be adaptive by "design" not an ad hoc change of the trial conduct and analysis daptation is a prospective design feature, not a remedy for poor planning
37 General Structure n adaptive design requires the trial to be conducted in several stages with access to the accumulated data n adaptive design may have one or more rules: llocation Rule: how subjects will be allocated to available arms Sampling Rule: how many subjects will be sampled at next stage Stopping Rule: when to stop the trial (for efficacy, harm, futility) Decision Rule: the terminal decision rule and interim decisions pertaining to design change not covered by the previous three rules t any stage, the data may be analyzed and next stages redesigned taking into account all available data
38 Examples Group Sequential Designs: only Stopping Rule Response daptive llocation: only llocation Rule Sample Size Re-assessment: only Sampling Rule Flexible Designs: Changing the randomization ratio Changing the timing of the next interim analysis Changing the stopping Rule Changing the target treatment difference; changing the primary endpoint; varying the form of the primary analysis; modifying the patient population; etc nything goes?
39 chieving the goals There are plenty of available designs on statistician s shelf The greatest challenge is their implementation daptive designs have much more to offer than the rigid conventional parallel group designs in clinical trials
40 Group Sequential Design Determine N Conduct of Clinical Trial Final nalysis Interim analysis Interim analysis Interim analysis 3 Scope of Early termination of trial Overwhelming efficacy futility of the drug 4
41 Group sequential designs large study is a a huge investment, $, ethics What if the drug doesn t work or is much better than expected? Could we take an early look at data and stop the study is it look good (or too bad)? Group Sequential Methods with pplications to Clinical Trials by Christopher Jennison and ruce W. Turnbull.
42 Group Sequential Designs Group sequential designs are used to facilitate the conduct of interim analysis (see section 4.5 and Glossary). While group sequential designs are not the only acceptable types of designs permitting interim analysis, they are the most commonly applied because it is more practicable to assess grouped subject outcomes at periodic intervals during the trial than on a continuous basis as data from each subject become available. The statistical methods should be fully specified in advance of the availability of information on treatment outcomes and subject treatment assignments (i.e. blind breaking, see Section 4.5).
43 n Independent Data Monitoring Committee (see Glossary) may be used to review or to conduct the interim analysis of data arising from a group sequential design (see Section 4.6). While the design has been most widely and successfully used in large, long-term trials of mortality or major nonfatal endpoints, its use is growing in other circumstances. In particular, it is recognised that safety must be monitored in all trials and therefore the need for formal procedures to cover early stopping for safety reasons should always be considered.
44 Theoretical set-up Population I N (µ, σ =) Population II N (µ, σ =) x, x,., x N y, y,., y N Effect size, = µ - µ Our interest is to test (using two sample Z-test) H o : = vs H a : > ssuming = δ, total sample size (N) per population 44
45 Group-sequential structure Trial (K-) Interim Final Initiatio nalyses naly L- L K- n sis K dditional Subjects Cumulative Subjects Information Time n N n N n L- N L- n L N L n K- N K- n K N K =N Observed Effect size L- L K- K -sample Z Test Statistic T T T L- T L T K- T K Critical values Reject H o & Stop trial if: C C C L- C L C K- C K 45 T >C T >C T L- >C L- T L >C L T K- >C K- T K >C K
46 Conditional Power The conditional power evaluated at the L th interim analysis Sample size may be modified based on conditional power. { } is the Rejection Region. 46
47 Repeated significance test can we use same rejection limit for all interims? Let: ~ N, Y Test: ij Test statistic: j ˆ ˆ Z mk mk H : ˆ mk j Y ij mk i For k, K If Z k C Stop, reject For k K If H otherwise Continue to group k Z k C Stop, reject H otherwise stop accept H
48 True type I error rate Repeat testing until H rejected Tests Critical value P(type I error) Too high! Want to control error rate so that overall error rate = 5%
49 Pocock s test Suppose we want to test the null hypothesis 5 times using the same critical value each time and keep the overall significance level at 5% k If Z C K For, K fter group K Choose C p, K k p, Stop, reject otherwise Continue to group k Stop, reject H If Z C K Such that k p, otherwise stop accept H P( Reject H at any analysis k K) H
50 Pocock s test Z k Reject H.43 ccept H stage k -.43 Reject H.43 Nominal sign level.6%
51 Group sequential tests K c c
52 O rian & Flemmings test Increasing nominal significance levels decreasing rejection limits For, K k : If Z C, K K k fter group K : Choose C p, K k p / Stop, reject otherwise Continue to group k If Z C K k p, Stop, reject H otherwise stop accept H Such that P( Reject H at any analysis k K) H
53 O rian & Flemmings test Critical values and nominal significance levels for a O rian Flemming test with 5 interrim tests. Test (k) C (K,) C (K,)*Sqrt(K/k) Rather close to 5%
54 Group sequential tests Rather close to 5% K c c
55 O rian & Flemmings test Z k Stage K
56 Comparing Pocock and O rian Flemming O rian Flemming Pocock Test (k) C (K,a)*Sqrt(K/k) C P (K,a)
57 Comparing Pocock and O rian Flemming 6 4 Zk Stage k
58 Group Sequential Designs Pros: Efficiency Gain (Decreasing marginal benefit) Establish efficacy earlier Detect safety problems earlier Cons: Smaller safety data base Complex to run Need to live up to stopping rules!
59 Chapter 5 Reading Instructions 5.: Introduction 5.: Parallel Group Designs (read) 5.3: Cluster Randomized Designs (less important) 5.4: Crossover Designs (read+copies) 5.5: Titration Designs (read) 5.6: Enrichment Designs (less important) 5.7: Group Sequential Designs (read include.6) 5.8: Placebo-Challenging Designs (less important) 5.9: linded Reader Designs (less important) 5.: Discussion
Adaptive Model-Based Designs in Clinical Drug Development. Vlad Dragalin Global Biostatistics and Programming Wyeth Research
Adaptive Model-Based Designs in Clinical Drug Development Vlad Dragalin Global Biostatistics and Programming Wyeth Research 2007 Rutgers Biostatistics Day February 16, 2007 Outline Definition and general
More informationAlternative Trial Designs
Alternative Trial Designs STATS 773: DESIGN AND ANALYSIS OF CLINICAL TRIALS Dr Yannan Jiang Department of Statistics May 16 th 01, Wednesday, 08:30-10:00 Standard Design of RCT Individual subject is randomly
More informationHow To Design A Clinical Trial. Statistical Analysis. Gynecologic Cancer InterGroup
How To Design A Clinical Trial Statistical Analysis Andrew Embleton PhD student/medical Statistician MRC Clinical Trials Unit at UCL At what points do you need to consider statistics? At what points do
More informationShort Course: Adaptive Clinical Trials
Short Course: Adaptive Clinical Trials Presented at the 2 Annual Meeting of the Society for Clinical Trials Vancouver, Canada Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical
More informationField trial with veterinary vaccine
١ Field trial with veterinary vaccine Saeedeh Forghani,, M.D. Clinical Trial and Ethics Department Human Health Management Deputy of Quality Assurance 89/4/2 ٢ ٣ Introduction: The efficacy and safety shall
More informationOptimal design of multi-arm multi-stage (MAMS) clinical trials. James Wason, Thomas Jaki
Optimal design of multi-arm multi-stage (MAMS) clinical trials James Wason, Thomas Jaki Introduction - multi-arm trials In some therapeutic areas, there may be several possible agents/treatments awaiting
More informationGroup Sequential Monitoring of Clinical. Trials with Multiple Endpoints. Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK
Group Sequential Monitoring of Clinical Trials with Multiple Endpoints Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK Stanford February 2004 1 Example 1: A diabetes trial O
More informationClinical trial design issues and options for study of rare diseases
Clinical trial design issues and options for study of rare diseases November 3, 2016 Jeffrey Krischer, PhD Rare Diseases Clinical Research Network Rare Diseases Clinical Research Network (RDCRN) is coordinated
More information(Draft) Guideline on multiplicity issues in clinical trials
www.pei.de (Draft) Guideline on multiplicity issues in clinical trials Forum Biomedizinische Arzneimittel 14.06.2017 The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health. Statistical
More informationCombining Phase IIb and Phase III. Clinical Trials. Christopher Jennison. Partnerships in Clinical Trials,
Combining Phase IIb and Phase III Clinical Trials Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Partnerships in Clinical Trials, Brussels,
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationUniversity of Bath, UK
Group Sequential Selection Procedures with Elimination and Data-Dependent Treatment Allocation Christopher Jennison, Dept of Mathematical Sciences, University of Bath, UK http:wwwbathacuk mascj Manchester,
More informationInterim Analysis of Randomized Clinical Trials. David L DeMets, PhD
Interim Analysis of Randomized Clinical Trials David L DeMets, PhD Need for Data Monitoring Phase I Trials (dose) Monitoring usually at local level Phase II Trials (activity) Most monitoring at local level
More informationAnna Mennenga, Grand Valley State University Monica Ahrens, University of Iowa Dr. Eric Foster, Assistant Professor (Clinical), Dept.
The Consequences of Cluster Randomization in Phase III Clinical Trial Interim Analyses Anna Mennenga, Grand Valley State University Monica Ahrens, University of Iowa Dr. Eric Foster, Assistant Professor
More informationSample size Re estimation and Bias
Sample size Re estimation and Bias Medical University of Vienna, January 4, 03 Frank Miller, Stockholm University, Sweden Partly joint work with Tim Friede, Dept. of Medical Statistics, University Medical
More informationDesigning a Cost-effective Dose-finding Phase 2 Trial with Adaptive Design
Designing a Cost-effective Dose-finding Phase 2 Trial with Adaptive Design Key Concepts of a Cost-effective Adaptive Design Incorporating evaluation of efficacy and safety (tolerability) Dose-Response
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle (randomization) 3.4 Trial monitoring: Interim decision and group sequential designs Bios 6648- pg 1 (a) Recruitment and
More informationAdaptive Design for Medical Device Development
Adaptive Design for Medical Device Development A guide to accelerate clinical development and enhance portfolio value Executive Summary In May 2015, the FDA released a draft guidance document regarding
More informationHeterogeneity Random and fixed effects
Heterogeneity Random and fixed effects Georgia Salanti University of Ioannina School of Medicine Ioannina Greece gsalanti@cc.uoi.gr georgia.salanti@gmail.com Outline What is heterogeneity? Identifying
More informationThe Promise of Novel Clinical Trial Designs. Michael Parides, Ph.D. Mount Sinai School of Medicine
The Promise of Novel Clinical Trial Designs Michael Parides, Ph.D. Mount Sinai School of Medicine Productivity New Drug Approvals (NMEs) R&D Spending (billions) $12 $13 $13 $15 $49 $38 $39 $43 $30 $32
More informationSession 4: Statistical considerations in confirmatory clinical trials II
Session 4: Statistical considerations in confirmatory clinical trials II Agenda Interim analysis data monitoring committees group sequential designs Adaptive designs sample size re-estimation Phase II/III
More informationIntroduction to the Design and Evaluation of Group Sequential
SSCR ntroduction to the Design and Evaluation of Group Sequential Session 1 - Scientific Setting and mplications Presented July 27, 2016 Daniel L. Gillen Department of Statistics University of California,
More informationAdaptive Trials and Trial Simulation. Kert Viele CTMC 2018
Adaptive Trials and Trial Simulation Kert Viele CTMC 2018 Disclosures Berry Consultants Consulting firm specializing in Bayesian adaptive clinical trial design Multiple clients No off label use of specific
More informationAdaptive Design for Clinical Trials
Adaptive Design for Clinical Trials Mark Chang Millennium Pharmaceuticals, Inc., Cambridge, MA 02139,USA (e-mail: Mark.Chang@Statisticians.org) Abstract. Adaptive design is a trial design that allows modifications
More informationDocket #: FDA-2018-D-3268
Subject: Comment on FDA Draft Guidance for Industry Titled Rare Diseases: Early Drug Development and the Role of Pre-Investigational New Drug Application Meetings Docket #: FDA-2018-D-3268 ARM is an international
More informationFormalizing Study Design & Writing Your Protocol. Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care
TWIST: Formalizing Study Design & Writing Your Protocol Manish A. Shah, MD Weill Cornell Medicine Center for Advanced Digestive Care Presented by the Joint Clinical Trials Office/Quality Assurance Unit
More informationNuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards
Nuts & Bolts of Clinical Trials, DSMBs, Event Committees, Core Labs and Data Standards Ron Waksman, MD Professor of Medicine, Georgetown University Associate Chief of Cardiology, Washington Hospital Center
More informationIs Confirmatory PK/PD Modeling Possible?
Is Confirmatory PK/PD Modeling Possible? Chuanpu Hu, Ph.D. Director, Pharmacometrics Johnson & Johnson May 19, 2009 MBSW 2009 Outline PK/PD modeling why, how Exploratory vs. confirmatory: when to use which?
More informationNovel multiple testing procedures for structured study objectives and families of hypotheses a case study
Novel multiple testing procedures for structured study objectives and families of hypotheses a case study Guenther Mueller-Velten Novartis Pharma AG EMA Workshop on Multiplicity Issues in Clinical Trials
More information2015 AP Statistics Exam NAME
2015 AP Statistics Exam NAME (b) Suppose both corporations offered you a job for $36,000 a year as an entry-level accountant. (i) Based on the boxplots, give one reason why you might choose to accept the
More informationThe New Role of Drug Supply Planning in Adaptive Trials. Nitin R. Patel, Chairman and C.T.O. Cytel Inc.
The New Role of Drug Supply Planning in Adaptive Trials Nitin R. Patel, Chairman and C.T.O. Cytel Inc. Acknowledgements My colleagues at Cytel Suresh Ankolekar Pralay Senchaudhuri Judith Quinlan Clinical
More informationThe Plan of Enrichment Designs for Dealing with High Placebo Response
The Plan of Enrichment Designs for Dealing with High Placebo Response Xiangmin Zhang Division of Biometrics I/OB/OTS/CDER/FDA Joint work with Dr. Yeh-Fong Chen (FDA) and Prof. Roy Tamura (University of
More informationThe Promise and Challenge of Adaptive Design in Oncology Trials
THE POWER OFx Experts. Experience. Execution. The Promise and Challenge of Adaptive Design in Oncology Trials Clinical oncology trials are more complex and time consuming than those in any other therapeutic
More informationEastAdapt: Software for
EastAdapt: Software for Adaptive Sample Size Re-estimation Cytel Webinar Cambridge, MA Cyrus R. Mehta President, Cytel Corporation May 16, 2009 email: mehta@cytel.com web: www.cytel.com tel: 617-661-2011
More informationNon-Inferiority Trials: What are they and why are they so difficult?
Non-Inferiority Trials: What are they and why are they so difficult? David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research Saint-Luke Luke s s Mid America Heart Institute Professor of Medicine
More informationModels for Computer-Aided Trial & Program Design
Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What
More informationAn Overview of Bayesian Adaptive Clinical Trial Design
An Overview of Bayesian Adaptive Clinical Trial Design Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical
More informationEisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency
Eisuke Hida & Yuki Ando Biostatistics group Pharmaceuticals and Medical Devices Agency This is not an official PMDA guidance or policy statement. No official support or endorsement by the PMDA is intended
More informationI diversi tipi di disegno sperimentale
I diversi tipi di disegno sperimentale Eva Pagano SID Academy: Metodologia degli studi clinici in diabetologia Bologna, 20-21 marzo 2018 La dr.ssa Eva Pagano dichiara di NON aver ricevuto negli ultimi
More informationAn Introduction to Flexible Adaptive Designs
An Introduction to Flexible Adaptive Designs Roger J. Lewis, MD, PhD Department of Emergency Medicine Harbor-UCLA Medical Center David Geffen School of Medicine at UCLA Los Angeles Biomedical Research
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationFacilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods
Facilitating Antibacterial Drug Development: Bayesian vs Frequentist Methods Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics University of Washington The Brookings Institution May 9, 2010 First:
More informationMethods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) SYNOPSIS
B Methods in Clinical Cancer Research Workshop Format for Protocol Concept Synopsis Sheet (blank) elow is the format to follow for the concept sheet for protocols. It is based on the International Committee
More informationMRC Biostatistics Unit
MRC Biostatistics Unit Adrian Mander MRC Biostatistics Unit Hub for Trials Methodology Research Cambridge June 2014 Adrian Mander June 2014 1/12 MRC Biostatistics Unit The 4 themes DART Design and Analysis
More informationAn adaptive design for dose-response using the Normal Dynamic Linear Model (NDLM)
An adaptive design for dose-response using the Normal Dynamic Linear Model (NDLM) Mike K Smith 1, Mark F. Morris 1, Ieuan Jones 1, Andy P. Grieve 1, Keith Tan 2 1 Biostatistics and Reporting, PGRD Sandwich;
More informationModels of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics
Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability
More informationDMC member experience: studies with adaptive designs. P.Bauer Medical University of Vienna December 2007
DMC member experience: studies with adaptive designs P.Bauer Medical University of Vienna December 2007 A typical application: Dose selection and confirmative inference (the critical issue of combining
More informationBayesian Designs for Clinical Trials in Early Drug Development
Vol. 3, No. 6, June 007 Can You Handle the Truth? Bayesian Designs for Clinical Trials in Early Drug Development By St. Clare Chung and Miklos Schulz Introduction A clinical trial is designed to answer
More informationAnimal Research Ethics Committee. Guidelines for Submitting Protocols for ethical approval of research or teaching involving live animals
Animal Research Ethics Committee Guidelines for Submitting Protocols for ethical approval of research or teaching involving live animals AREC Document No: 3 Revised Guidelines for Submitting Protocols
More informationFit-for-purpose limits and Tolerance intervals: connecting the assay performance to the clinical trial
Fit-for-purpose limits and Tolerance intervals: connecting the assay performance to the clinical trial Astrid Jullion & Bruno Boulanger Exploratory Statistics Pharmacometrics Lou, living with epilepsy
More informationPharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs)
Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs) N. Seth Berry, PharmD Senior Scientific Advisor Quantitative Decision
More informationSample Size Calculations for the Development of Biosimilar Products Based on Binary Endpoints
Communications for Statistical Applications and Methods 2015, Vol. 22, No. 4, 389 399 DOI: http://dx.doi.org/10.5351/csam.2015.22.4.389 Print ISSN 2287-7843 / Online ISSN 2383-4757 Sample Size Calculations
More informationA Constrained Optimum Adaptive Design for Dose Finding in Early Phase Clinical Trials
A Constrained Optimum Adaptive Design for Finding in Early Phase Clinical Trials Iftakhar Alam Barbara Bogacka Steve Coad School of Mathematical Sciences Queen Mary University of London m.alam@qmul.ac.uk
More informationJennifer Pulley (Statistical Scientist)
A bioequivalence study design in Immunology which includes the option for sample size reestimation (SSR) at the Interim Analysis Jennifer Pulley (Statistical Scientist) Overview Study design Interactions
More informationΣχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) To demonstrate that two (or more) medicinal products are bioequivalent
Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) AIM OF BIOEQUIVALENCE STUDIES To demonstrate that two (or more) medicinal products are bioequivalent AND Two medicinal products
More informationMissing Data Handling in Non-Inferiority & Equivalence Trials
Missing Data Handling in Non-Inferiority & Equivalence Trials A systematic review Brooke A Rabe Graduate Interdisciplinary Program in Statistics The University of Arizona, Tucson, USA PSI s Pharmaceutical
More informationPage 78
A Case Study for Radiation Therapy Dose Finding Utilizing Bayesian Sequential Trial Design Author s Details: (1) Fuyu Song and (2)(3) Shein-Chung Chow 1 Peking University Clinical Research Institute, Peking
More informationFDA Drug Approval Process Vicki Seyfert-Margolis, Ph.D.
Speaker Comparing The Effectiveness Of New Drugs: Should The FDA Be Asking 'Does It Work' Or 'Does It Work Better'? Vicki L. Seyfert-Margolis, PhD Senior Advisor, Science Innovation and Policy U.S. Food
More informationThe BEST Platform. A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018
The BEST Platform A Modular Early-Phase Platform for Seamless Dose Finding and Cohort Expansion Laiya Consulting, Inc. 2018 Introduction The Bayesian early-phase seamless transformation (BEST) platform
More informationDiscussion. Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things
Discussion Design of Experiments in Healthcare, dose-ranging studies, astrophysics and other dangerous things 1 If you think bad, don t think much M.D. PhD. 2 Contopoulous-Ioannidis et al. Life Cycle of
More informationExperience with Adaptive Dose-Ranging Studies in Early Clinical Development
Experience with Adaptive Dose-Ranging Studies in Early Clinical Development Judith Quinlan MSc Vice President Adaptive Trials Cytel Inc. judith.quinlan@cytel.com Thanks to members of the PhRMA Adaptive
More informationChapter 4: Foundations for inference. OpenIntro Statistics, 2nd Edition
Chapter 4: Foundations for inference OpenIntro Statistics, 2nd Edition Variability in estimates 1 Variability in estimates Application exercise Sampling distributions - via CLT 2 Confidence intervals 3
More informationResponse Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University
Response Adjusted for Duration of Antibiotic Risk (RADAR) Scott Evans, Ph.D., M.S. Harvard University CTTI Statistical Think Tank Expert Meeting November 19, 2014 Special Thank You Kunal Merchant Dan Rubin
More informationBayesian analysis for small sample size trials using informative priors derived from historical data
EFSPI & BBS Small populations and level of evidence Bayesian analysis for small sample size trials using informative priors derived from historical data /////////// Andreas Kaiser Bayer AG, Pharmaceuticals
More informationEfficacy, Safety and Futility Stopping Boundaries
Efficacy, Safety and Futility Stopping Boundaries ExL Pharma Workshop Philadelphia, PA Feb 25-26, 2007 Cyrus R. Mehta President, Cytel Inc. email: mehta@cytel.com web: www.cytel.com tel: 617-661-2011 1
More informationThe use of model based dose response in choosing doses in a lean clinical development plan. Alun Bedding, PhD
The use of model based dose response in choosing doses in a lean clinical development plan Alun Bedding, PhD What is Different About this Program? First in Human Proof of Concept/Dose Finding Conclusions
More informationKey multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials
Key multiplicity concepts and principles addressed in the Draft Guidance: Multiple Endpoints in Clinical Trials Mohammad F. Huque, Ph.D. Office of Biostatistics OTS, CDER/FDA DIA Annual Meeting, Boston,
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationImproving the validity and quality of our research Daniël Lakens Eindhoven University of
Improving the validity and quality of our research Daniël Lakens Eindhoven University of Technology @Lakens / Human-Technology Interaction 1-2-2016 PAGE 1 Sample Size Planning / Human-Technology Interaction
More informationGuiding dose escalation studies in Phase 1 with unblinded modeling
Guiding dose escalation studies in Phase 1 with unblinded modeling Andreas Krause Lead Scientist Modeling & Simulation Andreas.Krause@idorsia.com Basel Biometrics Section (BBS) Seminar: Innovative model-based
More informationSecond Quarter 2017 Financial Results. August 8, 2017
Second Quarter 2017 Financial Results August 8, 2017 Agios Conference Call Participants Prepared Remarks Introduction RENEE LECK, Sr. Manager, Investor Relations Business Highlights & 2017 Key Milestones
More informationThe Effect of an Unplanned Sample Size Re-Estimation on the Type I Error Rate
The Effect of an Unplanned Sample Size Re-Estimation on the Type I Error Rate Leslie A. McClure 1, Jeff M. Szychowski 1, Oscar Benavente 2, Robert G. Hart 3 & Christopher S. Coffey 4 1 Department of Biostatistics,
More information8. Clinical Trial Assessment Phase II
8. Clinical Trial Assessment Phase II Junko Sato, PhD Office of New Drug I, PMDA Disclaimer: The information within this presentation is based on the presenter s expertise and experience, and represents
More informationMinimal cost designs for an early phase clinical study
Minimal cost designs for an early phase clinical study Lee Kien Foo Stephen Duffull School of Pharmacy University of Otago Introduction Designs for PKPD studies mainly focus on improving the precision
More informationSAMPLE SIZE RE-ESTIMATION FOR BINARY DATA VIA CONDITIONAL POWER
SAPE SIZE RE-ESIAION FOR BINARY DAA VIA ONDIIONA POWER. Wang, D.S. Keller and K.K.G an. Wang and D.S. Keller, Pfizer Inc, Groton, 06340 K.K.G. an, Aventis Pharmaceuticals, Bridgewater, NJ 08807 Key Words:
More informationDMC membership experience. P.Bauer Basel May 2016
DMC membership experience P.Bauer Basel May 2016 EMA GUIDELINE ON DATA MONITORING COMMITTEES Clinical trials frequently extend over a long period of time. Thus, for ethical reasons it is desirable to ensure
More information3 Phases of Investigation
Part I: The scientific setting - December 30, 2009, 1 3 Phases of Investigation As discussed in Chapter 1, science is adversarial; scientists should consider all possible hypotheses, and only eliminate
More informationOn being Bayesian Namur 13 October 2016
On being Bayesian Namur 13 October 2016 Stephen Senn (c) Stephen Senn 2016 1 Acknowledgements Thank you for the kind invitation This work is partly supported by the European Union s 7th Framework Programme
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Assessing Protocol Feasibility
Date of version: 01 April 2012 Replaces previous version: 201.01 01 June 2011 Study Start-Up SS-201.02 STANDARD OPERATING PROCEDURE FOR Assessing Protocol Feasibility Approval: Nancy Paris, MS, FACHE President
More informationProof of Concept Vs Proof of Value
Evidence Requirements Supporting Critical Decisions in Pharmacotherapeutics: Proof of Concept Vs Proof of Value RG Peterson MD, PhD, MPH Executive Director Drug Safety and Effectiveness Network Canadian
More information(Some of the) UnifyPow Workshop Examples
(Some of the) UnifyPow Workshop Examples, Cleveland Clinic Foundation Ordinary 2-group t-test comparing two independent means Dr. Seth Alalgia 1 is planning a study assess whether a new form of biofeedback
More informationSample Size and Power Calculation for High Order Crossover Designs
Sample Size and Power Calculation for High Order Crossover Designs Roger P. Qu, Ph.D Department of Biostatistics Forest Research Institute, New York, NY, USA 1. Introduction Sample size and power calculation
More informationExperience with Bayesian Clinical Trial Designs for Cardiac Medical Devices
Experience with Bayesian Clinical Trial Designs for Cardiac Medical Devices Andrew Mugglin Statistics Manager Cardiac Rhythm Management Clinical Research Medtronic, Inc. Acknowledgements with thanks to
More informationStatistical Considerations
Version 1.3 Effective date: 21 May 2012 Author: Approved by: Dr Ranjit Lall, Research Fellow Statistician Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 21 May 2012 Version
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle Lecture schedule Nov 11: Special topics and designs 5.1 Design and analysis of crossover studies 5.2 Design and evaluation
More informationAlternative Study Designs and their Suitability for Paediatric Development
Alternative Study Designs and their Suitability for Paediatric Development Frank Pétavy Biostatistics and Methodology Support, Medicines Evaluation Division Workshop on the development of new medicinal
More informationGEN-003. Positive Phase 2b Clinical Efficacy Results. Immunotherapy Candidate for Genital Herpes. 12-Month Top-line Results
GEN-003 Positive Phase 2b Clinical Efficacy Results Immunotherapy Candidate for Genital Herpes 12-Month Top-line Results Disclaimer This presentation contains forward-looking statements that are within
More informationMarcia Brackman, Data Scientist Eli Lilly and Company
k Marcia Brackman, Data Scientist Eli Lilly and Company Adaptive Design: A clinical study design that uses accumulating data to decide how to modify aspects of the study as it continues, without undermining
More informationBACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING
DATA AND SAFETY MONITORING September 2009 Joey Casanova, BBA, CIP Human Subject Research Office SECTION 1 BACKGROUND PURPOSE Data and safety monitoring is the process for reviewing accumulated outcome
More informationTrial-design in biosimilar research: Equivalence or non-inferiority design
Trial-design in biosimilar research: Equivalence or non-inferiority design Prof. Kit C.B. Roes Professor of Clinical Trial Methodology Advisor to MEB-CBG Overview The place(s) of the clinical efficacy
More informationRegulatory Perspective on the Value of Bayesian Methods
American Course on Drug Development and Regulatory Sciences Substantial Evidence in 21st Century Regulatory Science Borrowing Strength from Accumulating Data April 21, 2016 Regulatory Perspective on the
More informationAP Statistics Scope & Sequence
AP Statistics Scope & Sequence Grading Period Unit Title Learning Targets Throughout the School Year First Grading Period *Apply mathematics to problems in everyday life *Use a problem-solving model that
More informationAPPRAISAL OF CLINICAL TRIALS. Su May Liew CEBM Oxford
APPRAISAL OF CLINICAL TRIALS Su May Liew CEBM Oxford Good study Experimental - RCT Fit question - PICO Passes appraisal - RAMMbo Minimises random error - statistics Why a trial? It may be better to do
More informationIntroduction to Adaptive Design Roger J. Lewis, MD, PhD
Introduction to Adaptive Design Roger J. Lewis, MD, PhD Financial Disclosures Berry Consultants, LLC Multiple clients U01 Support from National Institutes of Health/NINDS Food and Drug Administration AspenBio
More informationBios 6648: Design & conduct of clinical research
Bios 6648: Design & conduct of clinical research Section 3 - Essential principle 3.2 Treatment allocation (randomization) 3.3 Study quality control 3.4 Trial monitoring: Interim decision and group sequential
More informationFDA Perspective on Clinical Trial Design for Rare Diseases
FDA Perspective on Clinical Trial Design for Rare Diseases American Statistical Association Biopharm Workshop Sept, 2018 Lucas Kempf, M.D. Associate Director Rare Diseases Program (acting) Office of New
More informationApplication of Modeling and Simulation to Support Clinical Drug Development Decisions in Alzheimer's Disease
Application of Modeling and Simulation to Support Clinical Drug Development Decisions in Alzheimer's Disease Marc R. Gastonguay, Ph.D. Scientific Director, Metrum Institute marcg@metruminstitute.org President
More informationTailoring best practices for the evaluation of endpoints in clinical device trials
Tailoring best practices for the evaluation of endpoints in clinical device trials George Dangas, MD, PhD Cardiac Safety Research Consortium 11 th March, 2016 ROADMAP Study blinding challenges Variability
More informationJune 15, Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB
June 15, 2016 Adaptive Phase I Studies: The IRB Perspective Marilyn Teal, PharmD IRB Member, Schulman IRB About Schulman IRB Established in 1983 Superior audit history with FDA five consecutive audits
More information